Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis
Open Access
- 1 October 2005
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 64 (10) , 1519-1520
- https://doi.org/10.1136/ard.2004.032821
Abstract
Despite combination treatment (ciclosporin 300 mg/day, fluocortolone 10 mg/day, and methotrexate (MTX)15 mg/week intramuscularly), disease activity was still high, and intravenous infliximab at 3 mg/kg was administered initially at weeks 0, 2, 6, 14 and then every 6 weeks. Ciclosporin was withdrawn.Keywords
This publication has 8 references indexed in Scilit:
- Monitoring methotrexate‐induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?Alimentary Pharmacology & Therapeutics, 2004
- Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patientsAnnals of the Rheumatic Diseases, 2004
- Autoimmune hepatitisAutoimmunity Reviews, 2003
- Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathyArthritis & Rheumatism, 2003
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: Comment on the article by Charles et alArthritis & Rheumatism, 2001
- Infliximab-Associated Reversible Cholestatic Liver DiseaseMayo Clinic Proceedings, 2001
- Methotrexate and histologic hepatic abnormalities: A meta-analysisThe American Journal of Medicine, 1991